{
    "clinical_study": {
        "@rank": "116147", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: Momelotinib", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive momelotinib  for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 168 weeks."
            }, 
            {
                "arm_group_label": "Arm 2: Best Available Therapy (BAT)", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 168 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to determine the efficacy of momelotinib (MMB) versus best available therapy\n      (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or\n      post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) who\n      were treated with ruxolitinib as measured by splenic response rate at Week 24 (SRR24).\n\n      Participants will be randomized to receive either MMB or BAT for 24 weeks during the\n      randomized treatment phase, after which they will be eligible to receive MMB in an extended\n      treatment phase for up to an additional 168 weeks.  After discontinuation of study\n      medication, assessments will continue for 12 additional weeks, after which participants will\n      be contacted for survival follow-up approximately every 6 months for up to 5 years from the\n      date of enrollment."
        }, 
        "brief_title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF", 
        "completion_date": {
            "#text": "November 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Myelofibrosis (PMF),", 
            "Post-polycythemia Vera (Post-PV)", 
            "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Thrombocythemia, Essential", 
                "Thrombocytosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Palpable splenomegaly at least 5 cm below left costal margin\n\n          -  Confirmed diagnosis of PMF in accordance, or Post-PV/ET MF\n\n          -  Currently or previously treated with ruxolitinib for PMF or Post-PV/ET MF for at\n             least 28 days, and characterized by\n\n               -  Requirement for RBC transfusion while on ruxolitinib treatment, OR\n\n               -  Dose adjustment of ruxolitinib to < 20 mg twice daily at start of or during\n                  ruxolitinib treatment AND at least one of the following while on ruxolitinib\n                  treatment:\n\n                    -  \u2265 Common Terminology Criteria for Adverse Events (CTCAE) Grade 3\n                       thrombocytopenia, OR\n\n                    -  \u2265 CTCAE Grade 3 anemia, OR\n\n                    -  \u2265 CTCAE Grade 3 hematoma (bleed)\n\n          -  High risk OR intermediate-2 risk as defined by Dynamic International Prognostic\n             Scoring System (DIPSS), OR intermediate-1 risk as defined by DIPSS and associated\n             with symptomatic splenomegaly, and/or hepatomegaly\n\n          -  If receiving myelofibrosis therapy, must be on a stable dose of the same regimen for\n             at least 2 weeks prior to screen date and through the screening period\n\n          -  If not receiving myelofibrosis therapy, must remain off therapy for at least 2 weeks\n             prior to screen date and through the screening period\n\n          -  Acceptable laboratory assessments obtained within 14 days prior to Day 1\n\n               -  Absolute neutrophil count (ANC) > 0.75 x 10^9/L in the absence of growth factor\n                  in the prior 7 days\n\n               -  Peripheral blood blast count < 10%\n\n               -  Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 3 x the upper\n                  limit of the normal range (ULN) (\u2264 5 x ULN if liver is involved by\n                  extramedullary hematopoiesis as judged by the investigator or if related to iron\n                  chelator therapy that was started within the prior 60 days)\n\n               -  Calculated creatinine clearance of \u2265 45 mL/min\n\n               -  Direct bilirubin \u2264 2.0 x ULN\n\n          -  Life expectancy > 24 weeks\n\n          -  Negative serum pregnancy test for female subjects (unless surgically sterile or\n             greater than two years post-menopausal)\n\n          -  Males and females of childbearing potential must agree to use protocol-specified\n             method(s) of contraception\n\n          -  Females who are nursing must agree to discontinue nursing before the first dose of\n             MMB\n\n          -  Able to understand and willing to sign informed consent form (ICF)\n\n        Exclusion Criteria:\n\n          -  Prior splenectomy\n\n          -  Splenic irradiation within 3 months prior to Day 1\n\n          -  Use of investigational agent within 28 days prior to Day 1\n\n          -  Prior treatment with MMB\n\n          -  Hematopoietic growth factor (granulocyte growth factor, erythropoiesis stimulating\n             agent, thrombopoietin mimetic) within 28 days prior to Day 1\n\n          -  Uncontrolled inter-current illness, per protocol\n\n          -  Known positive status for human immunodeficiency virus (HIV)\n\n          -  Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C\n             carrier\n\n          -  Presence of peripheral neuropathy \u2265 CTCAE Grade 2\n\n          -  Unwilling or unable to undergo a MRI or CT Scan per study protocol requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101268", 
            "org_study_id": "GS-US-352-1214", 
            "secondary_id": "2013-005007-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1: Momelotinib", 
                "description": "Momelotinib tablet administered orally once daily", 
                "intervention_name": "Momelotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-0387", 
                    "CYT387"
                ]
            }, 
            {
                "arm_group_label": "Arm 2: Best Available Therapy (BAT)", 
                "description": "Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.", 
                "intervention_name": "Best Available Therapy (BAT)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib", 
        "overall_contact": {
            "email": "momelotinib.studies@gilead.com", 
            "last_name": "Clinical Study Contact"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Peter Lee, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Splenic response rate at Week 24 is defined as the proportion of participants achieving a \u2265 35% reduction in spleen volume at Week 24 from baseline as measured by MRI or CT.", 
            "measure": "Splenic response rate at Week 24", 
            "safety_issue": "No", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total symptom score (TSS) is defined as the proportion of participants who achieve a \u2265 50% reduction in TSS from baseline to Week 24 as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) v2.0 diary.", 
                "measure": "Response rate in total symptom score at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Rate of RBC transfusion is defined as the average number of RBC units per participant per month.", 
                "measure": "Rate of red blood cell (RBC) transfusion through Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "description": "RBC transfusion independence is the proportion of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the prior 12 weeks.", 
                "measure": "RBC transfusion independence rate at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "RBC transfusion dependence is the proportion of participants who are transfusion dependent at Week 24, defined as at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in the prior 8 weeks.", 
                "measure": "RBC transfusion dependence rate at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}